Mycosis Fungoides - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 65 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Mycosis Fungoides - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Mycosis Fungoides - Pipeline Review, H2 2014', provides an overview of the Mycosis Fungoides's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mycosis Fungoides, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycosis Fungoides and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mycosis Fungoides
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Mycosis Fungoides and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mycosis Fungoides pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mycosis Fungoides
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mycosis Fungoides pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mycosis Fungoides Overview 6
Therapeutics Development 7
Pipeline Products for Mycosis Fungoides - Overview 7
Pipeline Products for Mycosis Fungoides - Comparative Analysis 8
Mycosis Fungoides - Therapeutics under Development by Companies 9
Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes 10
Mycosis Fungoides - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Mycosis Fungoides - Products under Development by Companies 13
Mycosis Fungoides - Products under Investigation by Universities/Institutes 14
Mycosis Fungoides - Companies Involved in Therapeutics Development 15
Sanofi 15
Seattle Genetics, Inc. 16
Echo Therapeutics, Inc. 17
Actelion Ltd 18
Mycosis Fungoides - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
brentuximab vedotin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
mechlorethamine hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
alemtuzumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
methotrexate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
NSC-678515 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CIGB-128 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Mycosis Fungoides - Recent Pipeline Updates 41
Mycosis Fungoides - Product Development Milestones 60
Featured News & Press Releases 60
Apr 08, 2014: Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS in Key Countries 60
Nov 18, 2013: Actelion launches VALCHLOR gel 0.016% in the US 61
Jan 30, 2013: Ceptaris Announces Publication In JAMA Dermatology Of Positive Clinical Results For Mechlorethamine Gel In Early Stage Mycosis Fungoides 62
Nov 26, 2012: Seattle Genetics Receives FDA Orphan Drug Designation For Adcetris To Treat Mycosis Fungoides 62
Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel 63
Oct 04, 2011: FDA Accepts Filing Of NDA For Yaupongel's Gel Formulation Of Mechlorethamine Hydrochloride 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Tables
Number of Products under Development for Mycosis Fungoides, H2 2014 7
Number of Products under Development for Mycosis Fungoides - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Mycosis Fungoides - Pipeline by Sanofi, H2 2014 15
Mycosis Fungoides - Pipeline by Seattle Genetics, Inc., H2 2014 16
Mycosis Fungoides - Pipeline by Echo Therapeutics, Inc., H2 2014 17
Mycosis Fungoides - Pipeline by Actelion Ltd, H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Mycosis Fungoides Therapeutics - Recent Pipeline Updates, H2 2014 41